Spyglass Pharma (NASDAQ:SGP) Stock Price Down 10.1% – Should You Sell?

Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) shares dropped 10.1% during trading on Monday. The company traded as low as $30.00 and last traded at $29.5510. 32,138 shares were traded during trading, a decline of 70% from the average daily volume of 108,111 shares. The stock had previously closed at $32.88.

Analysts Set New Price Targets

SGP has been the subject of several analyst reports. Weiss Ratings raised shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Friday. Stifel Nicolaus raised their target price on shares of Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday. HC Wainwright raised their target price on shares of Spyglass Pharma from $37.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday. Raymond James Financial assumed coverage on shares of Spyglass Pharma in a report on Friday, August 14th. They issued an “outperform” rating and a $39.00 price target on the stock. Finally, Citigroup raised their target price on Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Spyglass Pharma currently has an average rating of “Moderate Buy” and an average price target of $45.83.

View Our Latest Stock Analysis on SGP

Spyglass Pharma Trading Down 8.2%

The company’s 50-day moving average is $28.78 and its 200 day moving average is $24.83. The firm has a market cap of $1.01 billion and a PE ratio of -3.94.

Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.07). On average, research analysts predict that Spyglass Pharma, Inc. will post -2.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new position in shares of Spyglass Pharma during the first quarter worth approximately $308,000. Bank of New York Mellon Corp acquired a new stake in Spyglass Pharma in the 2nd quarter valued at $533,000. Bank of America Corp DE bought a new position in Spyglass Pharma during the 1st quarter valued at about $726,000. Monashee Investment Management LLC acquired a new stake in Spyglass Pharma during the 1st quarter valued at $2,461,000. Finally, Affinity Asset Advisors LLC acquired a new position in Spyglass Pharma during the 1st quarter worth about $6,478,000.

About Spyglass Pharma

(Get Free Report)

SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.

See Also

Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.